Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytogenetics in acute leukemia.

Krzysztof Mrózek1, Nyla A Heerema, Clara D Bloomfield

  • 1Division of Hematology and Oncology, The Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Room 1248B, The Ohio State University, Columbus, OH 43210-1228, USA. Mrozek-1@medctr.osu.edu

Blood Reviews
|March 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026
Same author

Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.

Blood·2026
Same author

Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia.

JCI insight·2026
Same author

circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias.

Blood·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Cytogenetic abnormalities in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are crucial for diagnosis and treatment. This review details major findings and their clinical relevance in adult leukemia.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Cytogenetic analyses in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) reveal numerous non-random chromosome abnormalities.
  • Molecular studies link these aberrations to specific genes involved in leukemogenesis.
  • Common aberrations serve as diagnostic and prognostic markers, guiding therapy selection.

Purpose of the Study:

  • To review the clinical relevance of major cytogenetic findings in adult AML and ALL.
  • To summarize current understanding of how chromosome aberrations impact leukemia classification and treatment.
  • To highlight the need for further research into less frequent recurrent aberrations.

Main Methods:

  • Review of current literature on cytogenetics in AML and ALL.

Related Experiment Videos

  • Analysis of the association between cytogenetic findings, molecular alterations, and clinical outcomes.
  • Synthesis of information for the World Health Organization classification of hematologic malignancies.

    • Main Results:

    • Major cytogenetic aberrations are integrated into leukemia classification and prognosis.
    • Specific aberrations correlate with distinct laboratory and clinical characteristics.
    • The prognostic significance of less common aberrations requires further investigation.

    Conclusions:

    • Cytogenetic analysis is fundamental in defining distinct leukemia entities and guiding treatment strategies.
    • Established aberrations are vital for diagnosis, prognosis, and therapeutic decisions in AML and ALL.
    • Further research is needed to elucidate the clinical impact of rarer cytogenetic abnormalities.